"Adverse Outcome Pathways" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Models connecting initiating events at the cellular and molecular level to population-wide impacts. Computational models may be at levels relating toxicology to adverse effects.
| Descriptor ID |
D000073931
|
| MeSH Number(s) |
E05.318.740.600.800.715.250 E05.599.395.040 N04.452.871.715.200 N06.850.505.715.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adverse Outcome Pathways".
Below are MeSH descriptors whose meaning is more specific than "Adverse Outcome Pathways".
This graph shows the total number of publications written about "Adverse Outcome Pathways" by people in this website by year, and whether "Adverse Outcome Pathways" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 1 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adverse Outcome Pathways" by people in Profiles.
-
Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework. Front Public Health. 2021; 9:638605.
-
Understanding COVID-19 through adverse outcome pathways - 2nd CIAO AOP Design Workshop. ALTEX. 2021; 38(2):351-357.
-
Postvaccination COVID-19 among Healthcare Workers, Israel. Emerg Infect Dis. 2021 04; 27(4):1220-1222.
-
Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PLoS One. 2020; 15(9):e0239799.
-
Automated EHR score to predict COVID-19 outcomes at US Department of Veterans Affairs. PLoS One. 2020; 15(7):e0236554.
-
A putative AOP for pneumonia related to COVID-19. Arch Toxicol. 2020 09; 94(9):3343-3345.
-
Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China. J Med Virol. 2020 11; 92(11):2821-2829.
-
Adverse outcome pathways: opportunities, limitations and open questions. Arch Toxicol. 2017 Nov; 91(11):3477-3505.
-
Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy. Sci Rep. 2017 06 14; 7(1):3490.